Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
---|---|---|---|---|---|---|
Q4 2023 | 71 | 3,383,953 | BBIO, BV, FSK, APP | 13F-HR | 2/14/2024 | 000146393124000006 |
Q3 2023 | 73 | 2,849,240 | BBIO, BV, FSK, APP | RESTATEMENT | 1/22/2024 | 000146393124000003 |
Q2 2023 | 71 | 3,229,395 | APP, BBIO, FSK, BV | 13F-HR | 8/14/2023 | 000172554723000244 |
Q1 2023 | 82 | 3,322,438 | APP, BBIO, FSK, BV | 13F-HR | 5/15/2023 | 000146393123000007 |
Q4 2022 | 126 | 2,963,177 | APP, BV, FSK, BBIO | 13F-HR | 2/14/2023 | 000146393123000004 |
Q3 2022 | 216 | 4,979,092 | APP, FISV, BV, LAUR | 13F-HR | 11/14/2022 | 000146393122000011 |
Q2 2022 | 264 | 7,521,335 | FISV, APP, BV, FSK | 13F-HR | 8/12/2022 | 000146393122000008 |
Q1 2022 | 276 | 11,028,774 | APP, FISV, BV, FSK | 13F-HR | 5/16/2022 | 000156761922011020 |
Q4 2021 | 208 | 18,227,569 | APP, FISV, EDR, BV | 13F-HR | 2/14/2022 | 000156761922004143 |
Q3 2021 | 185 | 20,050,165 | APP, FISV, BBIO, BV | 13F-HR | 11/15/2021 | 000156761921020504 |
Q2 2021 | 141 | 24,656,728 | APP, FISV, BBIO, IR | 13F-HR | 8/16/2021 | 000156761921015746 |
Q1 2021 | 101 | 19,849,035 | FISV, IR, BBIO, ASO | 13F-HR | 5/17/2021 | 000156761921010548 |
Q4 2020 | 60 | 19,711,494 | FISV, BBIO, IR, ASO | 13F-HR | 2/16/2021 | 000156761921004092 |
Q3 2020 | 65 | 17,509,665 | FISV, IR, BBIO, BV | 13F-HR | 11/16/2020 | 000156761920019910 |
Q2 2020 | 67 | 16,386,208 | FISV, IR, BBIO, BV | 13F-HR | 8/14/2020 | 000156761920015535 |
Q1 2020 | 50 | 15,675,657 | FISV, IR, BBIO, BV | 13F-HR | 5/15/2020 | 000156761920010611 |
Q4 2019 | 54 | 20,455,805 | FISV, IR, BBIO, BV | 13F-HR | 2/14/2020 | 000156761920003955 |
Q3 2019 | 52 | 17,777,800 | FISV, IR, BV, BBIO | 13F-HR | 11/14/2019 | 000156761919021529 |
Q2 2019 | 55 | 8,117,692 | IR, BV, BBIO, PRAH | 13F-HR | 8/14/2019 | 000156761919016938 |
Q1 2019 | 55 | 6,572,745 | IR, BV, PRAH, KREF | 13F-HR | 5/15/2019 | 000156761919011160 |
Q4 2018 | 56 | 5,483,174 | IR, PRAH, BV, KREF | 13F-HR | 2/13/2019 | 000156761919003744 |
Q3 2018 | 59 | 8,819,944 | IR, BV, EYE, PRAH | 13F-HR | 11/14/2018 | 000156761918006241 |
Q2 2018 | 51 | 8,783,164 | IR, BV, PRAH, EYE | 13F-HR | 8/14/2018 | 000156761918000992 |
Q1 2018 | 42 | 8,223,848 | IR, PRAH, EYE, KREF | 13F-HR | 5/15/2018 | 000114036118023893 |
Q4 2017 | 52 | 10,160,178 | IR, EYE, PRAH, KREF | 13F-HR | 2/14/2018 | 000114036118008215 |
Q3 2017 | 1 | 73,501 | WRD | NEW HOLDINGS | 2/14/2018 | 000114036118008207 |
Q3 2017 | 52 | 8,587,011 | IR, PRAH, USFD, KREF | 13F-HR | 11/14/2017 | 000114036117042773 |
Q2 2017 | 1 | 68,259 | WRD | NEW HOLDINGS | 2/14/2018 | 000114036118008196 |
Q2 2017 | 2 | 510,857 | KREF, VRS | NEW HOLDINGS | 11/14/2017 | 000114036117042748 |
Q2 2017 | 45 | 8,248,533 | IR, PRAH, USFD, GDDY | 13F-HR | 8/14/2017 | 000114036117031949 |
Q1 2017 | 1 | 60 | VRS | NEW HOLDINGS | 11/14/2017 | 000114036117042731 |
Q1 2017 | 1 | 9,790 | NOMD | NEW HOLDINGS | 6/29/2017 | 000114036117026686 |
Q1 2017 | 49 | 5,562,435 | USFD, PRAH, GDDY, ENGILITY HLDGS INC NEW | 13F-HR | 5/15/2017 | 000110465917032805 |
Q4 2016 | 1 | 71 | VRS | NEW HOLDINGS | 11/14/2017 | 000114036117042723 |
Q4 2016 | 53 | 6,267,982 | USFD, PRAH, GDDY, HCA | 13F-HR | 2/14/2017 | 000110465917009304 |
Q3 2016 | 1 | 65 | VRS | NEW HOLDINGS | 11/14/2017 | 000114036117042720 |
Q3 2016 | 56 | 8,056,345 | USFD, WBA, PRAH, GDDY | 13F-HR | 11/14/2016 | 000110465916156936 |
Q2 2016 | 51 | 9,494,163 | WBA, USFD, PRAH, GDDY | 13F-HR | 8/15/2016 | 000110465916139802 |
Q1 2016 | 53 | 10,094,057 | WBA, PRAH, HCA, ZBH | 13F-HR | 5/16/2016 | 000110465916121432 |
Q4 2015 | 55 | 10,275,349 | WBA, PRAH, HCA, ZBH | RESTATEMENT | 4/1/2016 | 000110465916109348 |
Q3 2015 | 69 | 9,408,496 | WBA, PRAH, HCA, ZBH | RESTATEMENT | 4/1/2016 | 000110465916109340 |
Q2 2015 | 58 | 11,072,574 | WBA, PRAH, HCA, SJM | RESTATEMENT | 4/1/2016 | 000110465916109337 |
Q1 2015 | 90 | 9,646,047 | WBA, PRAH, HCA, SJM | 13F-HR | 5/15/2015 | 000110465915038732 |
Q4 2014 | 82 | 7,661,282 | WBA, HCA, PRAH, NLSN | 13F-HR | 2/17/2015 | 000110465915011324 |
Q3 2014 | 88 | 3,530,395 | HCA, NLSN, WBA, GILEAD SCIENCES INC | 13F-HR | 11/14/2014 | 000110465914081036 |
Q2 2014 | 78 | 3,401,065 | HCA, NLSN, WBA, RNET | 13F-HR | 8/14/2014 | 000110465914061103 |
Q1 2014 | 134 | 5,964,150 | HCA, NLSN, MRVL, NXPI | RESTATEMENT | 8/14/2014 | 000110465914061093 |
Q4 2013 | 126 | 5,946,266 | HCA, NLSN, NXPI, MRVL | 13F-HR | 2/14/2014 | 000110465914010629 |